Prilenia Email Format
Biotechnology ResearchMassachusetts, United States51-200 Employees
Prilenia is a clinical-stage biotechnology company focused on developing treatments for neurodegenerative and neurodevelopmental disorders. Its lead candidate, pridopidine, is an oral, first-in-class drug with an established safety profile and potential across multiple movement disorders and neurodegenerative diseases affecting adults and children. The company is led by Dr. Michael Hayden, MD, PhD, a biotech veteran who has founded several companies and previously served as President of Global R&D and Chief Scientific Officer at Teva, with a track record of guiding drug programs to approvals. Prilenia operates across multiple locations, including Boston, Massachusetts; Naarden, Netherlands; and Herzliya, Israel. Prilenia is advancing pridopidine in Huntington’s disease in the global Phase 3 PROOF-HD trial and in ALS in the Phase 2/3 HEALEY platform trial. Recent leadership appointments during 2024 reflect ongoing organizational development.